A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus (“AAV”)). We believe that the ARCUS platform’s key capabilities and differentiating characteristics can be leveraged for effective and safe therapeutic outcomes. Overview of Genome Editing DNA carries the genetic instructions for all basic functions of a living cell.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 34M | 34M | 69M | 49M | - | 116M |
| Net Income | -46M | -46M | 7.2M | -61M | -112M | -31M |
| EPS | $-3.56 | $-3.56 | $1.04 | $-478.80 | $-1,143.00 | $-15.60 |
| Free Cash Flow | -66M | -66M | -59M | -86M | -49M | -16M |
| ROIC | -402.6% | -61.5% | 12.7% | -149.3% | -135.1% | -32.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.31 | 0.31 | 0.53 | 2.84 | 0.41 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -52M | -52M | -26M | -44M | -62M | -39M |
| Operating Margin | -152.2% | -152.2% | -38.1% | -89.8% | - | -34.1% |
| ROE | -49.6% | -61.5% | 12.7% | -325.1% | -184.7% | -33.6% |
| Shares Outstanding | 13M | 13M | 25M | 0M | 0M | 2M |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | 1.1B | N/A | 116M | N/A | 49M | 69M | 34M | 34M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 45M | 82M | 98M | 115M | 46M | 53M | 60M | 54M | 54M |
| SG&A | 14M | 27M | 36M | 40M | 41M | 39M | 35M | 32M | 32M |
| EBIT | -48M | -87M | -110M | -39M | -62M | -44M | -26M | -52M | -52M |
| Op. Margin | N/A | -8.1% | N/A | -34.1% | N/A | -89.8% | -38.1% | -152.2% | -152.2% |
| Net Income | -46M | -93M | -109M | -31M | -112M | -61M | 7.2M | -46M | -46M |
| Net Margin | N/A | -8.7% | N/A | -26.5% | N/A | -125.8% | 10.4% | -133.4% | -133.4% |
| Non-Recurring | 0 | 0 | 0 | 92K | 11M | 10M | -436K | -385K | -385K |
| Returns on Capital | |||||||||
| ROIC | -115.2% | -67.1% | -57.8% | -32.7% | -135.1% | -149.3% | 12.7% | -61.5% | N/M |
| ROE | -115.2% | -67.1% | -245.4% | -33.6% | -184.7% | -325.1% | 12.7% | -61.5% | -49.6% |
| ROA | -33.2% | -39.5% | -72.6% | -14.5% | -46.9% | -38.4% | 5.3% | -31.4% | -29.6% |
| Cash Flow | |||||||||
| Op. Cash Flow | -52M | -71M | -87M | -11M | -46M | -84M | -58M | -66M | -66M |
| Free Cash Flow | -66M | -96M | -92M | -16M | -49M | -86M | -59M | -66M | -66M |
| Owner Earnings | -57M | -85M | -110M | -36M | -73M | -105M | -74M | -77M | -77M |
| CapEx | 14M | 25M | 5.0M | 5.1M | 3.3M | 2.0M | 250K | 85K | 85K |
| Maint. CapEx | 2.4M | 5.3M | 8.8M | 9.0M | 7.8M | 6.8M | 3.4M | 1.5M | 1.5M |
| Growth CapEx | 12M | 19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 2.4M | 5.3M | 8.8M | 9.0M | 7.8M | 6.8M | 3.4M | 1.5M | 1.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 2.5M | 8.9M | 14M | 17M | 19M | 14M | 13M | 10M | 10M |
| Debt Repayment | 0 | 0 | 0 | 2.5M | 2.5M | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | N/A | -169M | -278M | -354M | -180M | -56M | -87M | -82M |
| Cash & Equiv. | 103M | 181M | 90M | 144M | 190M | 117M | 86M | 111M | 111M |
| Long-Term Debt | N/A | N/A | N/A | 2.5M | 22M | 22M | N/A | N/A | 29M |
| Debt/Equity | 2.47 | 0.70 | 0.24 | 0.10 | 0.41 | 2.84 | 0.53 | 0.31 | 0.31 |
| Interest Coverage | N/A | -479.1 | -603.5 | -298.3 | -56.1 | -19.6 | -14.7 | -36.7 | -36.7 |
| Equity | 40M | 138M | 44M | 91M | 60M | 19M | 56M | 92M | 92M |
| Total Assets | 139M | 235M | 150M | 211M | 238M | 160M | 136M | 154M | 154M |
| Total Liabilities | 99M | 97M | 106M | 120M | 178M | 141M | 80M | 62M | 62M |
| Intangibles | 1.5M | 1.4M | 1.4M | 2.0M | 731K | 400K | 622K | 1.2M | 1.2M |
| Retained Earnings | -85M | -177M | -286M | -317M | -428M | -490M | -482M | -528M | -528M |
| Working Capital | 102M | 167M | 63M | 126M | 139M | 86M | 80M | 110M | 110M |
| Current Assets | 116M | 194M | 106M | 162M | 199M | 136M | 95M | 119M | 119M |
| Current Liabilities | 14M | 27M | 43M | 36M | 60M | 50M | 15M | 8.9M | 8.9M |
| Per Share Data | |||||||||
| EPS | -87.60 | -66.30 | -62.70 | -15.60 | -1,143.00 | -478.80 | 1.04 | -3.56 | -3.56 |
| Owner EPS | -32.99 | -60.87 | -63.24 | -18.53 | -315.55 | -300.43 | -3.01 | -6.03 | -6.03 |
| Book Value | 23.32 | 98.74 | 25.55 | 46.47 | 262.14 | 53.98 | 2.28 | 7.18 | 7.18 |
| Cash Flow/Share | -30.19 | -50.69 | -50.26 | -5.53 | -198.46 | -240.74 | -2.36 | -5.13 | -3.45 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.7M | 1.4M | 1.7M | 2.0M | 0.2M | 0.3M | 24.7M | 12.8M | 12.8M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 4.5 | N/A | -2.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 4.3 | 10.4 | 5.1 | 1.4 | 2.3 | 0.6 | N/A | 1.0 |
| Price/Sales | N/A | N/A | N/A | 5.4 | N/A | 1.6 | 1.0 | N/A | 2.7 |
| FCF Yield | N/A | -16.2% | -20.0% | -3.4% | -57.6% | -201.8% | -183.2% | N/A | -71.0% |
| Market Cap | N/A | 590M | 463M | 466M | 85M | 43M | 32M | 0 | 93M |
| Avg. Price | N/A | 348.39 | 232.13 | 316.95 | 72.92 | 20.60 | 10.26 | 0.00 | 7.23 |
| Year-End Price | N/A | 421.50 | 266.10 | 237.30 | 29.10 | 11.10 | 4.65 | 0.00 | 7.23 |
PRECISION BIOSCIENCES INC passes 0 of 9 quality checks, indicating weak fundamentals.
PRECISION BIOSCIENCES INC trades at 7.0x trailing earnings, compared to its 15-year median P/E of 4.5x, suggesting it is currently Expensive relative to its historical range.
PRECISION BIOSCIENCES INC (DTIL) has a current P/E ratio of 7.0, compared to its historical median P/E of 4.5. The stock is currently considered Expensive based on its historical valuation range.
PRECISION BIOSCIENCES INC (DTIL) has a 5-year average return on invested capital (ROIC) of -73.2%. This is below average and may indicate limited pricing power.
PRECISION BIOSCIENCES INC (DTIL) has a market capitalization of $93M. It is classified as a small-cap stock.
PRECISION BIOSCIENCES INC (DTIL) does not currently pay a regular dividend.
Based on historical P/E analysis, PRECISION BIOSCIENCES INC (DTIL) appears expensive. The current P/E of 7.0 is 55% above its historical median of 4.5.
PRECISION BIOSCIENCES INC (DTIL) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
PRECISION BIOSCIENCES INC (DTIL) reported annual revenue of $34 million in its most recent fiscal year, based on SEC EDGAR filings.
PRECISION BIOSCIENCES INC (DTIL) has a net profit margin of -133.4%. The company is currently unprofitable.
PRECISION BIOSCIENCES INC (DTIL) generated $-66 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PRECISION BIOSCIENCES INC (DTIL) has a debt-to-equity ratio of 0.31. This indicates a conservatively financed balance sheet.
PRECISION BIOSCIENCES INC (DTIL) reported earnings per share (EPS) of $-3.56 in its most recent fiscal year.
PRECISION BIOSCIENCES INC (DTIL) has a return on equity (ROE) of -61.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for PRECISION BIOSCIENCES INC (DTIL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PRECISION BIOSCIENCES INC (DTIL) has a book value per share of $7.18, based on its most recent annual SEC filing.